Sabon Farfadowa na iya jinkirta Ci gaban Cutar Alzheimer

Moleac ya sanar da sakin sakamakon binciken ATHENE, wanda aka buga a cikin Journal of the American Medical Director Association (JAMDA).

Jiyya da zasu iya rage jinkirin tsarin AD da zarar ya kai matakin asibiti, ya kasance muhimmin buqatar likita da ba ta cika ba. NeuroAiD ™ II ya nuna yana da tasirin daidaitawa akan sarrafa furotin amyloid precursor (APP) 2 da kuma canza furotin tau zuwa nau'ikan phosphorylated mara kyau da tarawa3, kazalika da abubuwan haɓakawa da haɓakar neuro-restorative4. An riga an nuna tasirin fa'ida na NeuroAiD™ II akan ayyukan fahimi mara kyau a cikin raunin kwakwalwa mai rauni5.

Therapy da cutar Alzheimer tare da Neuroaid (ATHENE) Nazarin shine bincike na farko don tantance aminci da ingancin NeuroAiD™II a cikin matsakaici zuwa matsakaicin marasa lafiya AD sun tsaya kan daidaitattun jiyya.

ATHENE wata 6 ce bazuwar makafi biyu, gwajin sarrafa wuribo wanda ke biye da buɗaɗɗen lakabin jiyya na NeuroAiD™II na wasu watanni 6. An saka batutuwa 125 daga Singapore a cikin shari'ar, wanda Cibiyar Kula da Lafiya ta Kasa, Iri na National National, Singapore.

• NeuroAiD™ II ya nuna aminci na dogon lokaci a matsayin ƙarin jiyya a cikin AD ba tare da haɓakar marasa lafiya da ke fuskantar ko dai mummunan al'amura ko abubuwan da suka faru ba.

• Farawa na farko na NeuroAiD ™ II ya ba da ingantaccen haɓakar fahimta na dogon lokaci idan aka kwatanta da placebo (ƙungiyar farkon farawa) wanda aka auna ta ADAS-cog, ƙididdiga mai mahimmanci a cikin watanni 9, da rage raguwa a kan lokaci.

Sakamakon binciken ATHENE yana goyan bayan fa'idar NeuroAiD ™ II azaman amintaccen jiyya ga daidaitaccen jiyya na AD kamar yadda binciken bai sami wata shaida mai girma a cikin abubuwan da ba su dace ba tsakanin MLC901 da placebo. Bincike ya ba da shawarar yuwuwar MLC901 a cikin rage jinkirin ci gaban AD wanda ya yi daidai da binciken da aka buga a baya da kuma na asibiti, yana mai da shi ingantaccen magani ga marasa lafiya AD. Waɗannan sakamakon suna buƙatar ƙarin tabbaci a cikin girma da tsayin karatu.                                                         

Kalma daga Babban Mai binciken

“Cutar Alzheimer ita ce mafi yawan sanadin cutar hauka, wanda ya kai kashi 60-80% na lokuta. Har sai kwanan nan amincewar aducanumab ta FDA, babu wata cuta da ke gyara maganin cutar Alzheimer, kuma a halin yanzu ana samun jiyya na alamun cutar na ɗan lokaci na ɗan lokaci da cutar da alamun cutar dementia da inganta ingancin rayuwa ga waɗanda ke da Alzheimer da masu kula da su. Don haka, akwai buƙatar baiwa majiyyata da masu kula da su damar samun ganewar asali da sabbin jiyya da wuri.

Ya kamata a fahimci sakamako mai ban sha'awa na binciken ATHENE a matsayin wani ɓangare na bututun haɓaka maganin cutar Alzheimer daga alamun bayyanar cututtuka zuwa hanyoyin magance cututtuka. Wannan binciken da sauran yuwuwar jiyya yakamata a tantance su ta hanyar ingantaccen gwaji na asibiti.”

Farfesa Christopher Chen

Darakta, tsufa na ƙwaƙwalwa, tsarin kiwon lafiya na ƙasa da kuma Mataimakin farfesa, Sashen Pharmology, Jami'ar Yong Loo Lin Lin Magunguna, Jami'ar Singapore.